NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis Holdings, LLC and Appoints Him as Board Observer and Strategic Advisor

Rhea-AI Summary

NEXGEL (NASDAQ:NXGL) announced that its previously disclosed spin-off, NexGelRx, received strategic investments from Eric Gruntfest and Ariel Imas of Diesis Holdings, LLC on Dec 16, 2025. In connection with the investment, NexGelRx appointed Eric Gruntfest as a board observer and strategic advisor.

Mr. Gruntfest brings over 20 years of experience in reimbursement strategy, payer solutions, and patient access, and currently serves as Managing Partner at Diesis Holdings and CEO of RMBB Health; his background includes senior roles at Medtronic, MiMedx, Shire, and Celgene. Management said his expertise will support commercialization and patient access for NexGelRx’s ultra-gentle hydrogel transdermal delivery products.

Key Figures

Industry experience over 20 years Eric Gruntfest’s healthcare leadership background

Market Reality Check

$0.2168 Last Close

Volume Volume 37,780 vs 20-day average 90,686, indicating relatively light pre-news trading. low

Technical Price $1.59 is trading below the 200-day MA of $2.43 and well under the $5.10 52-week high.

Peers on Argus

NXGL was down 4.79% while peers were mixed: HBIO -2.33%, BNGO -4.94%, but RVP +5.89% and POCI +2.89%, with MHUA -27.18%. Moves appear stock-specific rather than a uniform sector trend.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 11	Spin-off announcement	Positive	+22.7%	Spin-off of drug delivery assets into NexGelRx with royalty and equity stake.
Nov 11	Earnings release	Neutral	-4.6%	Q3 2025 results with flat revenue and improved gross margin.
Nov 03	Earnings preview	Neutral	-4.5%	Announcement of Q3 2025 report date and investor call logistics.
Oct 09	Conference appearance	Neutral	-1.5%	Planned LD Micro conference presentation by CEO with webcast access.
Aug 12	Earnings release	Positive	-11.4%	Strong Q2 2025 growth, margin expansion, non-dilutive capital and financing.

Pattern Detected

Recent news often aligns with price moves, with one notable divergence on strong Q2 2025 results.

Recent Company History

Over the last six months, NEXGEL has reported improving financials and executed strategic steps around its hydrogel platform. On Aug 12, strong Q2 2025 growth and margin expansion ($2.88M revenue, 43.6% margin) was followed by an -11.44% move. The Q3 2025 results on Nov 11 were essentially flat and drew a modest decline. On Dec 11, the NexGelRx spin-off with a 19.99% stake and 5% royalty prompted a 22.67% rise. Today’s additional investment into NexGelRx builds directly on that spin-off announcement.

Market Pulse Summary

This announcement extends the NexGelRx spin-off story by adding new capital and appointing an experienced healthcare executive as board observer and advisor. It reinforces external support for NEXGEL’s hydrogel-based transdermal delivery platform following the Dec 11 spin-off terms, which included a 19.99% equity stake and 5% royalty. Investors may monitor future NexGelRx financing, commercialization steps, and NEXGEL’s progress addressing earlier going-concern disclosures when evaluating long-term impact.

Key Terms

spin-off financial

"the Company’s previously announced spin-off of select drug delivery application assets"

A spin-off happens when a company creates a new, independent business by separating part of itself, like splitting off a division into its own company. This often happens so the new company can focus better on its own goals or attract different investors. It matters because it can lead to more growth opportunities and clearer focus for both companies.

hydrogel medical

"ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications"

A hydrogel is a soft, jelly-like material made mostly of water combined with a network of flexible, supportive molecules. Its unique ability to hold large amounts of water while remaining stable makes it useful in various medical, industrial, and consumer applications. For investors, innovations involving hydrogels can signal growth opportunities in sectors like healthcare, biotechnology, and advanced materials.

transdermal delivery medical

"innovative transdermal delivery mechanism for a wide array of pharmaceuticals"

Transdermal delivery is a way to get a medicine into the body through the skin, typically using patches, gels or creams that release the drug steadily into the bloodstream. For investors it matters because this route can improve patient convenience and adherence, enable steady dosing, reduce side effects, and create distinct product features and patents that affect market size, pricing power, and regulatory approval complexity.

AI-generated analysis. Not financial advice.

LANGHORNE, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that NexGelRx, the Company’s previously announced spin-off of select drug delivery application assets, has received strategic investments from Eric Gruntfest and Ariel Imas of Diesis Holdings, LLC. In connection with the investment, NexGelRx has appointed Mr. Gruntfest to serve as a board observer and advisor, bringing deep experience in reimbursement strategy, patient access, and healthcare-commercialization leadership.

Mr. Gruntfest is a seasoned healthcare executive with over 20 years of experience spanning reimbursement management, payer solutions, and patient support programs. He currently serves as Managing Partner for Diesis Holdings, LLC, and as Chief Executive Officer of RMBB Health, where he has strengthened market positioning and advanced patient access initiatives. His background includes senior leadership roles at Medtronic, MiMedx, Shire, and Celgene, with a strong record of building and leading high-performing teams across the healthcare ecosystem.

“We welcome Eric as both an investor and strategic advisor to NexGelRx,” said Richard Myers, CEO of NexGelRx. “His insight will bring an important new perspective to our company and add to the depth of our stakeholder base. We have a unique, ultra-gentle hydrogel product, and we look forward to demonstrating its potential as an ideal, innovative transdermal delivery mechanism for a wide array of pharmaceuticals.”

About NEXGEL, Inc.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal^®, Hexagels^®, Turfguard^®, Kenkoderm^® and Silly George^®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.

Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, the potential return on investment for our shareholders through a dedicated team and platform to pursue high-value Rx opportunities while NEXGEL remains focused on contract manufacturing and consumer branded products in the health and beauty space, the potential to unlock what we believe to be a potentially large opportunity without NEXGEL itself having to fund its development, that electron beam generated hydrogel lends itself to creating new topical and systemic therapies that can supplement existing therapies or create new ways to treat patients in a variety of clinical areas and the focus of using the hydrogel for drug delivery platform could lead to it becoming a platform for a family of useful and transformative therapies . These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.

Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@KCSA.com

FAQ

What did NEXGEL (NXGL) announce on December 16, 2025 about NexGelRx?

NEXGEL said NexGelRx received strategic investments from Eric Gruntfest and Ariel Imas and appointed Eric Gruntfest as board observer and strategic advisor.

Who is Eric Gruntfest and what role will he have at NexGelRx (NXGL)?

Eric Gruntfest is a managing partner at Diesis Holdings and CEO of RMBB Health; he will serve as a board observer and strategic advisor to NexGelRx.

How does NexGelRx describe the strategic value of Gruntfest’s appointment for NXGL shareholders?

The company said his reimbursement and patient access experience should support commercialization and stakeholder engagement for hydrogel transdermal delivery products.

Did NEXGEL disclose the investment amount from Diesis Holdings for NexGelRx?

No; the announcement disclosed strategic investments but did not provide a dollar amount or financing size.

What products will NexGelRx focus on after the investment by Diesis Holdings (NXGL)?

NexGelRx will focus on ultra-gentle, high-water-content hydrogel products and their use as transdermal drug delivery mechanisms.

Does the NexGelRx announcement indicate a change to NEXGEL’s corporate structure or spin-off timeline (NXGL)?

The announcement references the previously announced NexGelRx spin-off and reports the new investment and advisory appointment without providing timeline changes.